KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Assets Average (2016 - 2025)

Historic Assets Average for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $4.7 billion.

  • Alnylam Pharmaceuticals' Assets Average rose 1464.46% to $4.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 billion, marking a year-over-year increase of 1464.46%. This contributed to the annual value of $4.0 billion for FY2024, which is 940.35% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Assets Average stood at $4.7 billion, which was up 1464.46% from $4.4 billion recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Assets Average ranged from a high of $4.7 billion in Q3 2025 and a low of $3.3 billion during Q1 2021
  • Over the past 5 years, Alnylam Pharmaceuticals' median Assets Average value was $3.6 billion (recorded in 2021), while the average stood at $3.8 billion.
  • In the last 5 years, Alnylam Pharmaceuticals' Assets Average skyrocketed by 4251.71% in 2021 and then tumbled by 195.78% in 2023.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Assets Average stood at $3.6 billion in 2021, then dropped by 0.48% to $3.5 billion in 2022, then rose by 8.29% to $3.8 billion in 2023, then grew by 10.12% to $4.2 billion in 2024, then grew by 11.52% to $4.7 billion in 2025.
  • Its last three reported values are $4.7 billion in Q3 2025, $4.4 billion for Q2 2025, and $4.2 billion during Q1 2025.